普罗布考联合阿托伐他汀钙治疗急性脑梗死的疗效

doi:10.3969/j.issn.1673-5765.2024.10.006

摘要/Abstract

摘要： 目的评估普罗布考与阿托伐他汀钙联合治疗急性脑梗死（acute cerebral infarction，ACI）的疗效，以提供ACI的治疗参考方案。
方法回顾性收集2018年1月—2023年9月在重庆市急救医疗中心就诊，发病24 h内住院的ACI患者资料。纳入患者需满足：接受了阿托伐他汀钙（20 mg，每晚1次）单药或联用普罗布考（0.5 mg，每日2次）调节血脂治疗，且治疗周期为3个月以上。根据是否联用普罗布考分为联合治疗组和对照组，比较两组治疗后神经功能（使用NIHSS评估）、神经功能结局（使用mRS评估）、生活能力（使用Barthel指数评估）以及血脂水平的差异。
结果研究共入组102例患者，其中联合治疗组56例，对照组46例。两组的基线资料差异无统计学意义。治疗后14 d两组的NIHSS评分和血脂水平、治疗3个月后的血脂水平均较本组治疗前显著改善（均P<0.001）。治疗14 d时，联合治疗组的NIHSS评分（P=0.031）、TC（P=0.005）和LDL-C（P=0.044）水平低于对照组，Barthel指数（P=0.004）高于对照组，差异有统计学意义。治疗3个月时，联合治疗组的mRS评分（P＜0.001）、TC（P＜0.001）、TG（P=0.002）和LDL-C（P＜0.001）水平低于对照组，Barthel指数高于对照组（P＜0.001），差异有统计学意义。随访3个月期间联合治疗组的脑梗死复发率为0，对照组为2.17%，但差异无统计学意义（P=0.268）。
结论普罗布考联合阿托伐他汀钙治疗ACI急性期患者，相较于单独使用阿托伐他汀钙，具有更佳的临床疗效，能有效降低血脂水平并改善患者的神经功能及生活能力。

文章导读： 本研究通过回顾性的病历资料分析，发现普罗布考联合阿托伐他汀钙治疗急性脑梗死，能有效降低患者的血脂水平并改善其功能预后。

关键词: 急性脑梗死; 普罗布考; 阿托伐他汀钙; 神经功能; 血脂

Abstract: Objective To evaluate the effects of probucol combined with atorvastatin calcium in the treatment of acute cerebral infarction (ACI), with the aim of providing a therapeutic reference for ACI.
Methods Data of ACI patients hospitalized within 24 h of symptom onset at Chongqing Emergency Medical Center from January 2018 to September 2023 were retrospectively collected. Patients included in the study met specific criteria, which included receiving lipid-regulating therapy with atorvastatin calcium (20 mg, qn) monotherapy or combined with probucol (0.5 mg, bid) for a treatment duration exceeding 3 months. Patients were divided into the combined treatment group and the control group according to whether probucol was combined or not. The study compared differences in neurological function (measured by the NIHSS), neurological outcome (measured by the mRS), life ability [measured by the Barthel index], and lipid levels (including TC, TG, HDL-C and LDL-C) between the two groups.
Results A total of 102 patients were enrolled in the study, including 56 in the combined treatment group and 46 in the control group. There was no statistically significant difference in baseline data between the two groups. The NIHSS scores and lipid levels in both groups at 14 days post-treatment, as well as the lipid levels after 3 months of treatment, showed significant improvement compared to baseline controls (P<0.001). After 14 days of treatment, the NIHSS score (P=0.031), TC (P=0.005) and LDL-C (P=0.044) levels of the combined treatment group were lower than those of the control group, while the Barthel index score (P=0.004) was higher than that of the control group. The difference was statistically significant. After 3 months of treatment, the mRS score (P<0.001), TC (P<0.001), TG (P=0.002) and LDL-C (P<0.001) levels of the combined treatment group were lower than those of the control group, while the Barthel index score (P<0.001) was higher than that of the control group. The difference was statistically significant. The recurrence rate of cerebral infarction during the 3 months follow-up period was 0 in the combined treatment group and 2.17% in the control group. The difference was not statistically significant (P= 0.268).
Conclusions The combination of probucol and atorvastatin calcium in treating patients in the acute phase of ACI demonstrated superior clinical efficacy compared to atorvastatin calcium alone. This combination effectively reduced lipid levels and improved neurological function and ability to live.

Key words: Acute cerebral infarction; Probucol; Atorvastatin calcium; Neurological function; Lipid profile

中图分类号:

黄艳玲, 杨柳, 袁德智, 王谑菲, 王慧, 孟涛. 普罗布考联合阿托伐他汀钙治疗急性脑梗死的疗效[J]. 中国卒中杂志, 2024, 19(10): 1143-1147.

HUANG Yanling, YANG Liu, YUAN Dezhi, WANG Xuefei, WANG Hui, MENG Tao. Effects of Probucol Combined with Atorvastatin Calcium in the Treatment of Acute Cerebral Infarction[J]. Chinese Journal of Stroke, 2024, 19(10): 1143-1147.

参考文献

[1] GBD 2019 Stroke Collaborators. Global，regional，and national burden of stroke and its risk factors，1990-2019：a systematic analysis for the global burden of disease study 2019[J]. Lancet Neurol，2021，20（10）：795-820.
[2] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中国循环杂志，2023，38（3）：237-271.
Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management（2023）[J]. Chinese Circulation Journal，2023，38（3）：237-271.
[3] PFUETZE K D，DUJOVNE C A. Probucol[J]. Curr Atheroscler Rep，2000，2（1）：47-57.
[4] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志，2018，51（9）：666-682.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018[J]. Chin J Neurol，2018，51（9）：666-682.
[5] JIANG C X，ZHANG J B，ZHU J，et al. Association between coexisting intracranial artery and extracranial carotid artery atherosclerotic diseases and ipsilateral cerebral infarction：a Chinese Atherosclerosis Risk Evaluation（CARE-Ⅱ）study[J]. Stroke Vasc Neurol，2021，6（4）：595-602.
[6] AMARENCO P，BOGOUSSLAVSKY J，CALLAHAN A 3rd，et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med，2006，355（6）：549-559.
[7] 黄攀登，董利平，郭美丹，等. 普罗布考联合匹伐他汀治疗老年高血压合并脑梗死恢复期的临床疗效[J]. 中国实用神经疾病杂志，2023，26（11）：1378-1383.
HUANG P D，DONG L P，GUO M D，et al. Clinical efficacy of probucol combined with pivastatin in the treatment of senile hypertension complicated with cerebral infarction during convalescence[J]. Chinese Journal of Practical Nervous Diseases，2023，26（11）：1378-1383.
[8] 王艳玲，王雪梅. 普罗布考联合阿托伐他汀治疗多发脑血管狭窄合并主动脉弓溃疡斑块病例报道[J]. 中国卒中杂志，2024，19（2）：202-206.
WANG Y L，WANG X M. A case report on the treatment of multiple cerebral vascular stenosis with aortic arch ulcer plaque using probucol combined with atorvastatin[J]. Chin J Stroke，2024，19（2）：202-206.
[9] 卢平. 普罗布考联合阿托伐他汀钙治疗急性脑梗死的临床疗效及其对血脂和神经功能的影响[J]. 临床合理用药杂志，2020，13（3）：43-45.
LU P. Clinical efficacy of probuco combined with atorvastatin calcium on the treatment of acute cerebral infarction and their effects on blood lipid and nerve function[J]. Linchaung Heli Yongyao，2020，13（3）：43-45.
[10] GUO X K，WANG L，XIA X S，et al. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice[J/OL]. Biomed Pharmacother，2019，109：1445-1453[2023-02-22]. https://doi.org/10.1016/j.
biopha.2018.10.184.
[11] WANG Y L，BAI L，LIN Y，et al. Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits[J/OL]. Lipids Health Dis，2015，14：82[2023-02-22]. https://doi.org/10.1186/s12944-015-0083-5.
[12] HONG K S，KIM B J，LEE J Y，et al. Rationale and design of the preventIon of cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage（PICASSO）study：a randomized controlled trial[J]. Int J Stroke，2015，10（7）：1153-1158.

[1]	伊珞, 姜英玉, 孟霞, 姜勇, 王拥军, 谷鸿秋. 轻型急性缺血性卒中患者院内神经功能恶化预测模型的开发与验证研究[J]. 中国卒中杂志, 2024, 19(5): 524-531.
[2]	丁则昱, 姬泽强, 吴建维, 康开江, 赵性泉. 幕上高血压性脑出血微创颅内血肿抽吸引流术后早期神经功能恶化危险因素分析[J]. 中国卒中杂志, 2024, 19(5): 545-551.
[3]	张建村, 王新星, 仝海波. 血小板活化在急性脑梗死中的作用研究进展[J]. 中国卒中杂志, 2024, 19(5): 579-585.
[4]	中国卒中学会医疗质量管理与促进分会, 《中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明》编写组. 中国缺血性卒中及短暂性脑缺血发作患者血脂长期管理科学声明[J]. 中国卒中杂志, 2024, 19(4): 440-451.
[5]	陈思嘉, 潘培炎, 陈思琪, 彭菲, 米东华. 普罗布考联合他汀类药物治疗颈动脉斑块的meta分析[J]. 中国卒中杂志, 2024, 19(3): 299-309.
[6]	步红静, 马娜, 张盼盼, 刘远洪. 急性穿支动脉脑梗死患者早期神经功能恶化列线图的建立与验证[J]. 中国卒中杂志, 2024, 19(2): 158-166.
[7]	王艳玲, 王雪梅. 普罗布考联合阿托伐他汀治疗多发脑血管狭窄合并主动脉弓溃疡斑块病例报道[J]. 中国卒中杂志, 2024, 19(2): 202-206.
[8]	辛娜, 林琳, 白波, 田昭曾, 姜加林, 王韬. 急性脑梗死诊断编码临床决策支持系统的研究与应用[J]. 中国卒中杂志, 2024, 19(11): 1313-1320.
[9]	陈绪斌, 肖炜婷, 岳喜峰, 何能清, 曾小辉. 急性缺血性卒中患者静脉溶栓后血清微小RNA-874-3p、微小RNA-181a-5p及Wnt/β-catenin信号通路与神经功能预后的关系[J]. 中国卒中杂志, 2024, 19(10): 1162-1169.
[10]	王璐, 王健. 穿支动脉粥样硬化病患者早期神经功能恶化的研究进展[J]. 中国卒中杂志, 2023, 18(10): 1191-1195.
[11]	关翘楚, 谢子逸, 吕卫萍, 倪环宇, 李敬伟, 周俊山, 恽文伟, 李晓波, 张清秀, 徐运. 急性后循环大血管闭塞性脑梗死桥接治疗与直接血管内治疗的疗效和安全性对比研究[J]. 中国卒中杂志, 2023, 18(04): 456-462.
[12]	樊振梅, 王春钚, 谢婷, 郜风清. 肢体协调辅助装置结合VR训练对急性脑梗死颅内血管介入治疗患者步态平衡和表面肌电图的影响[J]. 中国卒中杂志, 2023, 18(02): 194-200.
[13]	刘甜甜, 霍会永, 相世峰, 刘超, 张文超, 李军涛. 单发皮层下梗死患者早期神经功能恶化与豆纹动脉关系的研究[J]. 中国卒中杂志, 2023, 18(02): 208-212.
[14]	田雨, 管玲, 王伊龙. 脑小血管病患者排尿功能紊乱与自主神经功能的相关性研究 [J]. 中国卒中杂志, 2023, 18(01): 76-82.
[15]	宋彦丽, 林杰, 武一平, 李晓晶, 刘改芬, 夏文静, 张玉英, 张晓林, 吕晨冉, 周红, 李凯, 薛斌, 陈玲玲, 张忠波, 彭晓. 邯郸市居民心脑血管病危险因素的流行现状及高血压知晓率、治疗率和控制率的影响因素研究 [J]. 中国卒中杂志, 2022, 17(12): 1360-1365.